OGEN (Oragenics) Total Liabilities: $1.31 Mil (As of Mar. 2026)


OGEN Oragenics Inc OGEN
30 GF Score
Price $0.59
! 1 Warning Sign
View Full Analysis

What is Oragenics Total Liabilities?

Oragenics OGEN +2.55% 30 Total Liabilities is $1.31 Mil as of Mar. 2026. GuruFocus rates OGEN with a GF Score™ of 30/100. The stock has 1 warning sign investors should review.

Oragenics's Total Liabilities for the quarter that ended in Mar. 2026 was $1.31 Mil.

Oragenics's quarterly Total Liabilities declined from Sep. 2025 ($2.87 Mil) to Dec. 2025 ($1.79 Mil) and declined from Dec. 2025 ($1.79 Mil) to Mar. 2026 ($1.31 Mil).

Oragenics's annual Total Liabilities declined from Dec. 2023 ($1.80 Mil) to Dec. 2024 ($1.68 Mil) but then increased from Dec. 2024 ($1.68 Mil) to Dec. 2025 ($1.79 Mil).

Oragenics Total Liabilities Historical Data

* Premium members only.

The historical data trend for Oragenics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oragenics Total Liabilities Chart

Oragenics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.75 1.75 1.80 1.68 1.79

Oragenics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.73 4.27 2.87 1.79 1.31
OGEN
30GF Score
Oragenics Inc OGEN
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oragenics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Oragenics's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1.786+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=1.79

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=10.068-8.281
=1.79

Oragenics's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1.308+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=1.31

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=7.49-6.182
=1.31

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $1.31 Mil mean?
Oragenics (OGEN) has a Total Liabilities of $1.31 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Oragenics and its competitors.
Is Oragenics' Total Liabilities too high?
Oragenics' current Total Liabilities is $1.31 Mil. Overall, Oragenics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Oragenics' Total Liabilities compare to ELOX and CPMV?
Oragenics' Total Liabilities of $1.31 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Oragenics and its competitors. Oragenics's current Total Liabilities is $1.31 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oragenics stock overvalued right now?
Oragenics (OGEN) has a current Total Liabilities of $1.31 Mil. The current Total Liabilities is $1.31 Mil. Oragenics' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Oragenics (OGEN), the current Total Liabilities is $1.31 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Oragenics Business Description

Address 9015 Town Center Parkway, Suite 143, Lakewood Ranch, FL, USA, 34202
Oragenics Inc is a development-stage biopharmaceutical company dedicated to the research and development of nasal delivery pharmaceutical therapies targeting neurological conditions and infectious diseases. The Company is currently focused on advancing the development and commercialization of its product candidate, ONP-002. ONP-002 is a fully synthetic, non-naturally occurring neurosteroid that is lipophilic and is designed to cross the blood-brain barrier, with the goal of reducing swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The Company's primary focus is on the development and commercialization of ONP-002 for the treatment of mild traumatic brain injury (mTBI), or concussion.
30GF Score

Get the complete analysis for OGEN

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.59
Price